Drug Trial Radar · NCT01430195
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
Last checked: Nov 20, 2026Latest source record: Mar 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jun 2011
Primary completion
May 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to look at the efficacy of afamelanotide, when combined with narrow-band ultraviolet B (NB-UVB) light, in patients with nonsegmental vitiligo. Afamelanotide is expected to speed up the repigmentation induced by NB-UVB light, leading to reducing frequency and doses of NB-UVB.
Conditions
- Vitiligo
Interventions
AfamelanotideDrug
NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
Narrow-Band UVB Light TreatmentProcedure
To be administered 3 times/week for 6 months. 72 treatments in total.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pigmentation of full body, face, trunk and extremities using the VASI and VETF scoresTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Henry Ford Medical Center
Detroit, Michigan
The Mount Sinai School of Medicine
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.